Maze Therapeutics has completed enrollment in its Phase II Horizon study, with more than 50 patients enrolled. An administrative analysis showed clear UACR reduction across a broad spectrum of patients and a response rate over 50%. The company said it has data in early 2027 and that its capital funds those catalysts into 2029.
MAZE · Maze Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 65%
- Last earnings
- Mar 25, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2025 to Nov 2026
Latest documents
Maze Therapeutics said its renal study enrolled over 50 patients, exceeding the prior target of 30 to 45. MZE782 began on schedule, with PKU data expected in 27, while a chronic kidney disease study is planned to start in 2027.
Maze Therapeutics reported positive MZE829 Phase 2 data in 15 patients, showing a clinically meaningful mean reduction in proteinuria without serious adverse events. Nine-month net loss was $116.9 million; cash and marketable securities totaled $477.0 million as of September 30, 2026.
Maze Therapeutics completed HORIZON enrollment in more than 50 patients across three cohorts, expects final MZE829 data in early 2027, and reported $477.0 million in cash, cash equivalents and marketable securities as of September 30, 2026.
Maze Therapeutics exchanged 2,776,007 shares of its common stock held by Frazier Life Sciences affiliates for pre-funded warrants to purchase an equivalent number of shares at $0.001 per share, leaving 53,931,889 shares outstanding as of October 16, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Discovery research and other programs | 3.45M | three months ended September 30, 2026 filing | — |
| MZE782 | 5.55M | three months ended September 30, 2026 filing | — |
| MZE829 | 7.06M | three months ended September 30, 2026 filing | — |
| net proceeds | $14.4M | three months ended September 30, 2026 filing | — |
| shares of its common stock | 548,723 | three months ended September 30, 2026 filing | — |
| weighted average price | $27.42 | three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MAZE
this stock
Maze Therapeutics, Inc.
|
$1.72B | -24.3% | — | — | 12.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 23
Maze Therapeutics has completed enrollment in its Phase II Horizon study, with more than 50 patients enrolled. An administrative analysis showed clear UACR reduction across a broad spectrum of patients and a response rate over 50%. The company said it has data in early 2027 and that its capital funds those catalysts into 2029.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MAZE | -8.6% | +1.2% | +29.2% | -0.4% | -24.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -0.1% | +10.4% | +38.3% | +8.4% | -25.4% |